Cytotoxicity of Conjugates of 188Re-Labeled Dendrimers and Monoclonal Antibodies Anti-ICO-25 (MUC1) and Anti-ICO-80 (CD5) Against SKOV-3 (Ovary Cancer) and Jurkat Tumor Cell Lines (T-Lymphoblstic Lymphoma)

• Published in: Pharmaceutical chemistry journal Vol. 52; no. 8; pp. 681 - 684
• Main Authors: Grigor’eva, E. Yu, Stukalov, Yu. V., Smirnova, A. V., Koldaeva, E. Yu, Kalygina, N. S., Kulakov, V. N., Baryshnikov, A. Yu
• Format: Journal Article
• Language: English
• Published: New York Springer US 01-11-2018
• Subjects: Medicine; Molecular-Biological Problems of Drug Design and Mechanism of Drug Action; Organic Chemistry; Pharmacology/Toxicology; Pharmacy; Re radioisotope; radioimmunotherapy; anti-ICO-25 (MUC1); anti-ICO-80 (CD5); therapy; monoclonal antibodies
• ISSN: 0091-150X; 1573-9031
• DOI: 10.1007/s11094-018-1880-8

Targeted radioimmunotherapy is a promising approach to radiotherapy. Tumor-specific compounds were synthesized using monoclonal antibodies anti-ICO-25 (MUC1) and anti-ICO-80 (CD5) labeled with the therapeutic radioisotope
188
Re. The specificity of the conjugates was demonstrated
in vitro
using SKOV-3 (ovary cancer) and Jurkat tumor cell lines (T-lymphoblastic lymphoma), which are known to have membrane surface receptors specific for the corresponding antibodies. Short-term survival tests revealed 90-93% death of tumor cells, indicating the proposed conjugates were promising for targeted delivery of diagnostic and therapeutic cancer drugs.